Compare Lululemon Athletica Inc (LULU) vs TG Therapeutics Inc (TGTX) Price & Performance

Lululemon (LULU) trades at $119.56, down 4.82% amid broader market weakness in premium retail. The stock shows strong fundamentals with consistent earnings beats (Q1 2026 EPS of $1.69 vs. $1.67 expected) and robust profitability (32.03% ROE, 17.13% net margin). Technical indicators signal bearish momentum with current price near key support at $119, while valuation metrics appear attractive with P/E of 10.17 and P/S of 1.32.

The investment case balances strong execution against sector headwinds. International growth, particularly in China, and operational improvements support upside potential toward the $129.29 consensus target. However, competitive pressures and consumer spending volatility present near-term risks. Analyst sentiment remains mixed with 40.85% buy ratings versus 52.11% hold recommendations.

TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.

The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.